NCT04055792 2023-06-28Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLCHenan Cancer HospitalPhase 2 Completed42 enrolled
NCT03416517 2019-02-15Anlotinib and Irinotecan for Ewing SarcomaPeking University People's HospitalPhase 1/2 Unknown47 enrolled